Venturpharm Pharmaceutical(Hainan)Limited.
-
Founded in:
2004-03-09 -
Country:
China -
Address:
No. 279 Nanhai Avenue, Haikou City -
Tax NO.:
914601007543894388 -
Registered Funds:
194.8706 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Gliclazide |
This drug is a hypoglycemic sulfonylurea-oral diabetes treatment drug. Gliclazide lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin. For type 2 diabetes, gliclazide can restore the first-phase insulin secretion peak in response to glucose and increase the second-phase insulin secretion. It can be seen that the insulin secretion response induced or stimulated by glucose after a meal is significantly increased.
More
This drug is a hypoglycemic sulfonylurea-oral diabetes treatment drug. Gliclazide lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin. For type 2 diabetes, gliclazide can restore the first-phase insulin secretion peak in response to glucose and increase the second-phase insulin secretion. It can be seen that the insulin secretion response induced or stimulated by glucose after a meal is significantly increased. |
21187-98-4 | 22 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Adefovir dipivoxil |
Extract from the above information
More
Extract from the above information |
142340-99-6 | 27 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Zolmitriptan |
Zolmitriptan is a selective 5-HTIB/ID receptor agonist that stimulates 5-HTIB/ID receptors on intracranial blood vessels (including arteriovenous anastomoses) and sympathetic nerves of the trigeminal nervous system, causing intracranial vasoconstriction and inhibiting the release of pro-inflammatory neuropeptides.
More
Zolmitriptan is a selective 5-HTIB/ID receptor agonist that stimulates 5-HTIB/ID receptors on intracranial blood vessels (including arteriovenous anastomoses) and sympathetic nerves of the trigeminal nervous system, causing intracranial vasoconstriction and inhibiting the release of pro-inflammatory neuropeptides. |
139264-17-8 | 37 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cilostazol |
This product and its metabolites are cyclic adenosine monophosphate (cAMP) phosphodiesterase III inhibitors (PDEIII inhibitors), which can reduce the degradation of cAMP by inhibiting the activity of phosphodiesterase, thereby increasing the cAMP level in platelets and blood vessels, inhibiting platelet aggregation and vasodilation.
More
This product and its metabolites are cyclic adenosine monophosphate (cAMP) phosphodiesterase III inhibitors (PDEIII inhibitors), which can reduce the degradation of cAMP by inhibiting the activity of phosphodiesterase, thereby increasing the cAMP level in platelets and blood vessels, inhibiting platelet aggregation and vasodilation. |
73963-72-1 | 30 |